Managing the sequence-specificity of antisense oligonucleotides in drug discovery.
about
RNase H sequence preferences influence antisense oligonucleotide efficiency.A Sensitive In Vitro Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides.Advances in therapeutic bacterial antisense biotechnology.Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds.Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice.Hydrogel-Assisted Antisense LNA Gapmer Delivery for In Situ Gene Silencing in Spinal Cord Injury.
P2860
Managing the sequence-specificity of antisense oligonucleotides in drug discovery.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Managing the sequence-specificity of antisense oligonucleotides in drug discovery.
@en
type
label
Managing the sequence-specificity of antisense oligonucleotides in drug discovery.
@en
prefLabel
Managing the sequence-specificity of antisense oligonucleotides in drug discovery.
@en
P2093
P2860
P921
P356
P1476
Managing the sequence-specificity of antisense oligonucleotides in drug discovery.
@en
P2093
Bo R Hansen
Morten Lindow
Peter H Hagedorn
Troels Koch
P2860
P304
P356
10.1093/NAR/GKX056
P407
P577
2017-03-01T00:00:00Z
2017-03-17T00:00:00Z